ImmunoVaccine Technologies, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Halifax Canada (2000)

Organization Overview

First Clinical Trial
2010
NCT01095848
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

ImmunoVaccine Technologies, Inc. (IMV Inc.)